{"id":"W4281951662","doi":"10.1038/s41375-022-01589-y","title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; National Cancer Institute; Incyte; Jazz Pharmaceuticals; Ariad Pharmaceuticals; Celgene; Gilead Sciences; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Bosutinib; Imatinib; Medicine; Internal medicine; Cumulative incidence; Adverse effect; Myeloid leukemia; Oncology; Surgery; Nilotinib; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009784207,0.0007991508,0.001089665,0.0001527946,0.001274556,0.0001083436,0.0009930155,0.0003318333,0.001915],"category_scores_gemma":[0.001421716,0.0006470094,0.0007854441,0.0006501068,0.0002965645,0.0002047423,0.0005256719,0.001592131,0.0002209952],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.04762982,"about_ca_system_score_gemma":0.01742392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00255933,"about_ca_topic_score_gemma":0.0007358661,"domain_scores_codex":[0.9941036,0.0003042071,0.001426247,0.001453912,0.001276922,0.001435173],"domain_scores_gemma":[0.9931678,0.003483286,0.0007295901,0.002082503,0.000136261,0.0004005486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5024602,0.001191229,0.00009373777,0.000235649,0.002034507,0.001037774,0.003019874,0.004632716,0.003898765,0.0005636095,0.3262683,0.1545636],"study_design_scores_gemma":[0.6518636,0.01222605,0.0004064942,0.0001482233,0.001018133,0.00007373199,0.0005314487,0.01351084,0.001720894,0.0001788231,0.3177144,0.0006072824],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750615,0.003664474,0.0001772248,0.0028629,0.004065136,0.006975174,0.003891192,0.0004392046,0.002863189],"genre_scores_gemma":[0.9710548,0.0003242847,0.00127512,0.001160089,0.008460777,0.004076595,0.008414598,0.0002504913,0.004983275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1539563,"threshold_uncertainty_score":0.9995981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05070338452773471,"score_gpt":0.32363280685004,"score_spread":0.2729294223223053,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}